Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges

Tuesday, Alnylam Pharmaceuticals Inc ALNY said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, met the primary endpoint. The data showed that zilebesiran resulted in clinically and statistically…#alny #zilebesiran #sbp #olmesartan #alnylam #rocheholdingsag #roche #williamblair #acc #attrcm
Source: Reuters: Health - Category: Consumer Health News Source Type: news